New Delhi: Scientists from India, Russia, Brazil and South Africa Will collaborate on research that will help develop or repurpose drugs against COVID-19.
According to an official statement on Monday, the collaborative effort of experts from bioinformatics, organic chemistry, medicinal chemistry, drug screening and parasitologists will be of great importance for the discovery of new efficient drugs against COVID-19.
The integration of efforts, knowledge and experience of scientists and experts from various fields will lead to optimization of the health system and health care in the country. BRIC Country, Department of Science and Technology said in the statement.
“Scientists from India, Russia, Brazil and South Africa will work together to reinvent, validate and synthesize lead compounds against key proteases and RNA replicons, enzymes that catalyze the replication of RNA, SARS-CoV-2,” it said.
The approach that can inhibit both the maturation and spread of the virus during infection in host cells could help in the production of new COVID-19 drugs with improved production methods.
The field of multi-stage targeted inhibitors of SARS-CoV-2 came to the fore a few months back WHO Declared Covid-19 as a global emergency.
The multi-step process involves replication, transcription and maturation of the viral genome.
These enzymes are controlled by proteases and RNA replication. “Preventing these effects will be key to fulfilling the dream of millions of people on this earth to develop/repurpose a drug molecule against COVID-19,” it said.
The scientists will also perform biochemical assays, including cytotoxicity lead compounds against the main protease and RNA dependent RNA polymerase of SARS-CoV-2, and conduct target validation of lead compounds through molecular dynamics simulations and biochemical methods.
While efforts have been made to selectively inhibit a single target enzyme of SARS-CoV-2, potential inhibitors effective against both the replication and maturation machinery of SARS-CoV-2 have not yet been found.
The Department of Science and Technology will support this research which brings together a range of expertise from several BRICS countries to bring solutions to the COVID-19 crisis that the world is currently grappling with.
According to an official statement on Monday, the collaborative effort of experts from bioinformatics, organic chemistry, medicinal chemistry, drug screening and parasitologists will be of great importance for the discovery of new efficient drugs against COVID-19.
The integration of efforts, knowledge and experience of scientists and experts from various fields will lead to optimization of the health system and health care in the country. BRIC Country, Department of Science and Technology said in the statement.
“Scientists from India, Russia, Brazil and South Africa will work together to reinvent, validate and synthesize lead compounds against key proteases and RNA replicons, enzymes that catalyze the replication of RNA, SARS-CoV-2,” it said.
The approach that can inhibit both the maturation and spread of the virus during infection in host cells could help in the production of new COVID-19 drugs with improved production methods.
The field of multi-stage targeted inhibitors of SARS-CoV-2 came to the fore a few months back WHO Declared Covid-19 as a global emergency.
The multi-step process involves replication, transcription and maturation of the viral genome.
These enzymes are controlled by proteases and RNA replication. “Preventing these effects will be key to fulfilling the dream of millions of people on this earth to develop/repurpose a drug molecule against COVID-19,” it said.
The scientists will also perform biochemical assays, including cytotoxicity lead compounds against the main protease and RNA dependent RNA polymerase of SARS-CoV-2, and conduct target validation of lead compounds through molecular dynamics simulations and biochemical methods.
While efforts have been made to selectively inhibit a single target enzyme of SARS-CoV-2, potential inhibitors effective against both the replication and maturation machinery of SARS-CoV-2 have not yet been found.
The Department of Science and Technology will support this research which brings together a range of expertise from several BRICS countries to bring solutions to the COVID-19 crisis that the world is currently grappling with.
.